12:00 AM
 | 
Jan 17, 2000
 |  BC Week In Review  |  Company News  |  Deals

Feminique Corp., Mova Laboratories Inc. deal

The companies signed a letter of intent under which FEMQ will sell its Mitolactol dibormodulcitol cancer compound to Mova, subject to the compound's approval by the FDA (see BioCentury, Jan....

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >